HTB March 2023 now online

This issue of HTB includes first reports from the 30th CROI held from 19–22 February 2023 in Seattle.

• Pipeline HIV drugs and formulations for treatment and PrEP

• Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses

• Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP

• Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection

• Efficacy of N6LS monotherapy correlated with baseline factors

• CAB/RPV-LA levels are not reduced after switching from efavirenz

• Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study

• Point-of-care testing for mothers and infants: results from the LIFE study

• Single dose doxycycline as PEP for STIs (DoxyPEP): five studies

• Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?

• Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young people